Synthesis and biological activity of prostaglandin analogs containing heteroatoms in the cyclopentane ring

Current Organic Chemistry

Volumn 9, Issue 5, 2005, Pages 419-457

  Biaggio, Francisco C ^a   Rufino, Alessandra R ^a   Zaim, Marcio H ^b   Zaim, Cristiane Y H ^a   Bueno, Mauro A ^a   Rodrigues, Alessandro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LIPIDS;

ACTIVE SUBSTANCE; BIOLOGICAL PROPERTIES; BROAD SPECTRUM; CENTRAL NERVOUS SYSTEMS; HETEROATOMS; INFLAMMATORY PROCESS; MEDIATING ROLES; NATURALLY OCCURRING; PERIPHERAL NERVOUS SYSTEM; SMOOTH MUSCLES;

BIOACTIVITY;

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; AZAPROSTACYCLIN; AZAPROSTANOID; CARBON DISULFIDE; CLOPROSTENOL; CORTICOSTEROID; CYCLOPENTANE; FLUPROSTENOL; HYDRAZINE DERIVATIVE; HYDROCHLORIC ACID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROSTACYCLIN; OXAPROSTANOID; OXATHIAPROSTANOID; OXAZOLE DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; THIAPROSTANOID; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFLAMMATION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROSTAGLANDIN METABOLISM; REGULATORY MECHANISM; SMOOTH MUSCLE; STOMACH ACID SECRETION; STRUCTURE ANALYSIS;

EID: 14844314996     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/1385272053174912     Document Type: Article

References (98)

1. Von Euler, U.S. Arch. Exp. Pathol.Pharmacol., 1934 175, 78.
2. Bergstrom, S.; Ryhage, R.; Samuelsson, B.; Sjovall, J. Acta Chem. Scand. 1962, 16, 501.
3. For a detailed history of their discovery, see: Newton, R. F.; Roberts, S. M. Prostaglandins and Thromboxanes, Butterworth Co (Publishers) Ltd., 1982, p8.
4. For a detailed prostaglandin nomenclature, see: Nelson, N. A. J. Med. Chem. 1974, 17, 911.
5. For a complete prostaglandin metabolism, see Ref.[3], p.16.
6. Collins, P. W. J. Med. Chem. 1986, 29, 437.
7. Lakvich, F. A.; Pashkovskii, F. S.; Koroleva, E. V. Russ. Chem. Rev. 1992, 61, 243.
8. Levkoeva, E. J.; Yakhontov, L. N. Russ. Chem. Rev. 1977, 46, 565.
9. Dombrovskii, V. A.; Fonskii, D. Yu. Khim.-Farm. Zh. 1993, 2, 48.
10. Collins, P. W.; Djuric, S. W. Chem. Rev. 1993, 93, 1533.
11. Burk, R. M.; Gac, T.S.; Garst, M. E.; Gibson, L. L.; Krauss, A. H.; Protzman, C. E.; Woodward, D. F. Bioorg. And Med. Chem. Lett. 1994, 4, 2103.
12. Smith, D. C.; Fuchs, P. L. J. Org. Chem. 1995, 60, 2692.
13. Rousseau, B.; Nydegger, F.; Gossauer, A.; B-Skalmowski, B.; Vorbrüggen, H. Synthesis 1996, 1336.
14. Fonskii, D. Y.; Bespalov, V. E.; Drombovskii, V. A. Russ. J. Org. Chem. 1997, 33, 1638.
15. Dikovskaya, K. I.; Mazur, T. V.; Turovskii, I. V.; Freimanis, Y. F.; Gavars, M. P. Russ. J. Org. Chem. 1997, 33, 1270.
16. Fürmeier, S.; Metzger, J. O. Eur. J. Org. Chem. 2003, 39, 885.
17. Vlattas, J.; Dellureficio, J.; Cohen, D. S.; Lee, W.; Clarke, F.; Dotson, R.; Mathis, J.; Zoganas, H. Bioorg. Med. Chem. Lett. 1994, 4, 2067.
18. Vlattas, I.; Dellureficio, J.; Cohen, D. S.; Lee, W.; Clarke, F.; Dotson, R.; Mathis, J. Zoganas, H. Bioorg. Med. Chem. Lett. 1994, 4, 2073.
19. Komiotis, D.; Lim, C. T.; Dieter, J. P.; Le Breton, G. C.; Venton, D. L. J. Med. Chem. 1992, 35, 3033.
20. Das, J.; Hall, S. E.; Nakane, M.; Haslanger, M. F.; Reid, J. A.; Garber, D.; Truc, V. C.; Harris, D. N.; Hedberg, A.; Ogletree, M.L. J. Med Chem. 1990, 33, 1741.
21. Nakane, M.; Reid, J. A.; Han, W. C.; Das, J.; Truc, V. C.; Haslanger, M. F.; Garber, D.; Harres, D. N.; Hedberg, A.; Ogletree, M. L.; Hall, S. E. J. Med. Chem. 1990, 33, 2465.
22. Kamata, S.; Haga, N.; Tsuri, T.; Uchida, K.; Kakushi, H.; Arita, H.; Hanasaki, K. J. Med. Chem. 1990, 33, 229.
23. Kelly, M. J.; Newton, R. F.; Roberts, S. M,; Whitehead, J. F. J. Chem. Soc. Perkin Trans. I 1990, 2352.
24. Lakhvich, F. A.; Pashkovskii, F. S.; Lis, L. G. Zh. Org. Khim. 1991, 27, 96.
25. Jones, R. C. F.; Schofield, J. J. Chem. Soc. Perkin Trans. I 1990, 375.
26. Rufino, A. R.; Biaggio, F. C. Tetrahedron Lett. 2001 42, 8559.
27. 2 receptor antagonists, see: Cross, P. E.; Dickinson, R. P. in Annual Reports in Medicinal Chemistry Bailey; D. M.; Ed.; Academic Press; New York, 1987; Vol. 22,'pp. 95.
28. Blanchette, M. A.; Choy, W.; Davis, J. T.; Esenfeld, A. P.; Masamune, J.; Roush, W. R.; Sakai, T. Tetrahedron Lett. 1984, 25, 2183.
29. Gemal, A. L.; Luche, J. L. J. Am. Chem. Soc. 1981 103, 5454.
30. The fast-moving and the slow-moving alcohol epimers were tentatively assigned the 15-S and 15-R configurations, respectively, on the basis of their TLC mobility compared to those of the natural prostaglandins and previous 7-oxabicycloheptyl prostaglandin analogues [31].
31. For a review of the pharmacology of 7-oxabicycloheptane analogues, see: Harris, D. N.; Hall, S. E.; Hedberg, A.; Ogletree,M. L. Drugs Future 1988, 13, 153.
32. Arachidonic acid (800 μM) and ADP (20 μM) induced platelet aggregation in platelet-rich plasma as described previously: Harris, D. N.; Phillips, M. B.; Michel, I. M.; Goldenberg, H. J.; Sprague, P. W. Antonaccio, M. J. Prostaglandins 1981, 22, 295.
33. -7 M serotonin. For details see: Ogletree, M. L.; Harris, D. N.; Greenberg, R.; Haslanger, M.; Nakane, M. J. Pharmacol. Exp. Ther. 1985, 234, 435.
34. 50 > 1000 μM for the corresponding tetrakisnor analogue.
35. Friedhoff, L. T.; Manning, J.; Funke, P. T.; Ivashkiv, E.; Tu, J.; Cooper, W.; Willard, D. A. Clin. Pharmacol. Ther. 1986 40, 634.
36. Misra, R. N. USPAT 5,550,248.
37. Misra, R. N. USPAT 5,135,939.
38. Misra, R. N. DD 299,186.
39. Sprague, P. W.; Heikes, J. E.; Gougoutas, J. Z.; Malley, M. F.; Harris, D. N.; Greenberg, R. J. Med. Chem. 1985, 28 1580.
40. This procedure was developed by Dr. Kronenthal, D., Chemical Process Research.
41. Nakane, M.; Reid, J. A.; Haslanger, M. F.; Garber, D. P.; Harris, D. N.; Ogletree, M. L.; Greenberg, R. In Advances in Prostaglandin and Thromboxane Research; Samuelsson, B.; Paoletti, R.; Ramwell, P.; Eds.; Raven: New York, 1985, Vol. 15, pp. 291.
42. For a detailed compilation of references to in vitro studies with (+)-6-(SQ 29,548), see ref. [31].
43. Grover, G. J.; Schumacher, W. A. Basic Res. Cardiol. 1989, 84, 103;
44. (b) Grover, G. J.; Fulmor, I. E. J Pharmacol. Exp. Ther. 1988, 247, 445;
45. (c) Grover, G. J.; Pharham, C. J. Circ. Res. 1989 64, 575;
46. (d) Grover, G. J.; Sleph, P. G.; Parham, C. S. Proc. Soc. Exp. Biol. Med. 1988, 188, 504;
47. (e) Grover, G. J.; Schumacher, W. A. J. Cardiovasc. Pharmacol. 1988, 11, 29.
48. Semicarbazide (+)-6 was shown to posses mutagenic potential in the Ames screen when incubated with a rat liver microsome fraction, 5-9 (metabolic activations).
49. A modification of the method described by Verheggen and Schror in which isomeric tension was used instead of isotonic tension: Verkeggen, R.; Schror, K. J. J. Cardiovasc. Pharmacol. 1986, 8, 483.
50. Corey, E. J.; Ponder, J. W.; Ulrich, P. Tetrahedron Lett. 1980, 21, 137;
51. (b) Nicolaou, K. C.; Magolda, R. L.; Claremon, D. A. J. Am. Chem. Soc. 1980, 102, 1404;
52. (c) Nicolaou, K. C.; Magolda, R. L.; Smith, J. B.; Aharony, A.; Smith, E. F.; Lefer, A. M. Proc. Nat. Acad. Sci. U.S.A. 1979 76, 2566;
53. (d) Wilson, N. H.; Jones, R. L. In: Advances in Prostaglandin and Thromboxane Research; Samuelsson, B. Paoletti, R.; Ramwell, P.; Eds.; Raven; New York, 1985, Vol. 14, pp. 393;
54. (e) Terres, W.; Kupper, W.; Hamm, C.; Bleifeld, W. Thromb. Haemostass 1987, 58, 181.
55. Nakane, M.; Reid, J. A.; Hasslanger, M. F.; Garber, D. P.; Harris, D. N.; Ogletree, M. L.; Greenberg, R. Adv. Prostaglandin Thromboxane Leukotriene Res. 1985, 15, 291.
56. Venton, D. L.; Enke, S. E.; Le Breton, G. C. J. Med. Chem. 1979, 22, 824.
57. Corey, E. J.; Schaaf, T. K.; Huber, W.; Kolliker, U.; Weinshenker, N. M. J. Am. Chem. Soc. 1970, 92, 397.
58. Herscovici, J.; Egron, M. J.; Antonakis, K. J. Chem. Soc., Perkin Trans. I 1982, 1967.
59. Johnson, C. R.; Shanklin, J. R.; Kirchoff, R. A. J. Am. Chem. Soc. 1973, 95, 6462.
60. Knights, E. F.; Brown, H. C. J. Am. Chem. Soc. 1968 90, 5280.
61. Corey, E. J.; Venkateswarlu, A. J. Am. Chem. Soc. 1972, 94, 6190.
62. Bernady, K. F.; Floyd, M. B.; Poletto, J. F.; Weiss, M. J. J. Org. Chem. 1979, 44, 1438.
63. Born, G. V. R. Nature (London) 1962, 194, 927.
64. Le Breton, G. C.; Venton, D. L.; Enke, S. E.; Halushka, P. V. Proc. Natt. Acad. Sci. U.S.A. 1979, 76, 4097.
65. Ogletree, M. L.; Harris, D. M.; Greenberg, R.; Haslanger, M. F.; Nakane, M. J. Pharmacol. Exp. Ther. 1985, 234, 435.
66. Narisada, M.; Ohtani, N.; Hagishita, S.; Seno, K.; Kamata, S.; Haga, N.; Tsuri, T.; Tsushima, T.; Kawada, K. USPAT 4,861,913.
67. Vlattas, I; Della Vecchia, L.; Lee, A. O. J. Am. Chem. Soc. 1976, 98, 2008.
68. Lumley, P.; White, B. P.; Humprey, P. P. A. Br. J. Pharmacol. 1989, 97, 783.
69. Vlattas, I.; Della Vecchia, L. Tetrahedron Lett. 1974, 4267.
70. Tentative stereochemical assignment is based on the assumption that stereoselective oxidation of the S-atom occurs via the less hindered α-side of the tetrahydrothiophene ring.
71. Campbell, J. B.; Collington, E. W.; Finch, H.; Hayes, R.; Lumley, P.; Mills, K.; Robertson, G. M.; Wharton, K.; Watts, J. S. Bioorg. Med. Chem. Lett. 1991, 1, 695.
72. Bhagwat, S. S.; Gude, C.; Cohen, D. S.; Lee, W.; Furness, P.; Clarke, F. H. J. Med. Chem. 1991, 34, 1790.
73. Ford, N. F.; Browne, L. J.; Campbell, T.; Gemenden, C. Goldstein, R.; Gude, C.; Wasley, J. W. F. J. Med. Chem. 1985, 28, 164.
74. Cohen, D.; McMartin, D.; Marietta, M.; Zane, P.; Lappe, R. Cardiovas. Drug Rev. 1992, 10, 379.
75. Capon, B.; McDowell, S. T.; Raftery, W. V. J. Chem. Soc., Perkin Trans. II 1973, 1118.
76. Prepared by DIBAL reduction of ethyl 2-tert butyldimethylsilyloxy acetate.
77. Gilman, H.; Spatz, S. M. J. Org. Chem. 1951, 16, 1485.
78. Carlock, J. T.; Mack, M. P. Tetrahedron Lett. 1978 5153.
79. Freyne, E. J.; Raeymaekers, A. H. M.; Venet, M. G.; Sipido, V. K.; Amd DeClerk, F. Drugs Future 1990, 15, 463.
80. Bhagwat, S. S.; Gude, C.; Boswell, C.; Contardo, N.; Cohen, D. S.;, Dotson, R.; Mathis, J.; Lee, W.; Furness, P.; Zoganas, H. J. Med. Chem. 1992, 35, 4373.
81. Hall, S. E.; Sher, P. M. USPAT 5,280,034.
82. Selliah, R.; Hellberg, M.; Klimko, P. G.; Sallee, V. L.; Zinke, P.W. PAT WO 97/23223.
83. Arndt, R. R.; Koekemoer, J. M.; Lourens, G. J.; Venter, E. M. S. African J. Chem. 1981, 34, 121.
84. Lourens, G. J.; Koekemoer, J. M. USPAT 4,133,817.
85. Selliah, S. E. USPAT 5,814,660.
86. Bock, K.; Pedersen, C.; Thogersen, H. Acta Chemica Scandinavica B 1981, 35, 441.
87. Hanessian, S.; Guindon, Y.; Lavalée, P.; Dextraze, P. Carbohydrate Research 1985, 141, 221.
88. Gaimes, M. S.; Delgado, P.; Conrow, R. E.; Dean, W. D. PAT. APLIC. PUB. US 2002/0002284.
89. Jackson, M.; Fox, M. E. PAT. APLIC. PUB. US 2003/0166948.
90. Klimko, P. G.; Hellberg, M. R. USPAT 6,211,226.
91. Verdoorn, G. H.; Holzapfel, C. W.; Braithwaite, D. H.; Von Platen, A. E. Syn. Comm. 1992, 22, 1813.
92. Syntex Inc. (USA) BE 841,165.
93. Elworthy T. R.; Mirzadegan, T.; Roepel, M. G.; Smith, D. B.; Walker, K. A. M. PAT WO 03/008377.
94. Elworthy, T. R.; Roepel, M. G.; Smith, D. B. PAT WO 03/007941.
95. Knight, D. R.; Cameron, K. O.; Lefker, B. A. PAT WO 03/077910.
96. Szabo, T.; Bódi, J.; Dalmadi, G.; Baloghné Kardos, Z.; Szeverenzi, Z. PAT WO 03/011849.
97. Araldi, G. L.; Liao, Y.; Zao, Z. WO 03/053923.
98. Araldi, G. L.; Zao, Z.; Reddy, A. P.; Mckenna, S. D.; Bao, B. WO 03/103604.